Firm’s carbohydrate-based candidates will be analyzed for antifibrotic effects.

Pro-Pharmaceuticals entered into a research collaboration with The Brigham and Women’s Hospital to evaluate the antifibrotic effects of some of the company’s carbohydrate compounds to treat acute and chronic kidney disease.


“We are encouraged by the effects our carbohydrate compounds had in the dissolution of scar tissue and reversal of liver fibrosis in animal models,” says Anatole Klyosov, Ph.D., chief scientist, Pro-Pharmaceuticals. “We plan to continue to validate our initial findings and to expand the use of these novel carbohydrate compounds in other fibrotic diseases.”


Pro-Pharmaceuticals’ carbohydrate-based compounds are also being investigated for the treatment of cancer, liver, microbial, cardiovascular, and inflammatory diseases as well as viral infections.

Previous articleRoche to Commercialize ARK’s Monitoring Tests for HIV Therapies
Next articleScientists Identify Gene that Influences Alcohol Consumption in Mice